Mural Oncology (MURA) - Uzoq muddatli qarzning kapitalga nisbati
Mural Oncology plc (MURA) uchun xatarlar daromadning yo'kligi va nemvalekin alfa sinovlaridagi potentsial muvaffaqiyatsizliklar bilan bog'liq. Biroq, saraton terapiyasi sektori YaIMdan mustaqil bo'lib, qat'iy FDA nazorati va ulkan R&D xarajatlari kirish uchun yuqori to'siqlarni yaratadi. Uzoq muddatli qarzning kapitalga nisbati dinamikasi moliyaviy barqarorlikni namoyish etadi, bunda parametr qiymati 0.00 ga tengdir.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261031&filename=GURU_Markets_-_MURA_-_Mural-Oncology-plc_-_Long-Term-Debt-to-Equity "Mural Oncology PLC (MURA): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi 21.02.2024dan 20.12.2025gacha | 👁️GURU.Markets👁️")
Mural Oncology plc kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Mural Oncology plc|MURA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati Mural Bio|MURA - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Mural Oncology plc|MURA - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Mural Oncology|Tezkor likvidlik koeffitsiyenti muraloncology.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
Kompaniyaning umumiy tahlili:muraloncology.com - MURA
Mural Oncology plc (MURA) uchun moliyaviy barqarorlik tashqi bog'liqliksiz klinik sinovlarni yakunlash qobiliyatini belgilaydi. Uzoq muddatli qarzdorlikning kapitalga nisbati ko'rsatkichini tahlil qilish orqali investor bir yildan ortiq muddatga tegishli kreditlarning kapitalga nisbatan ulushini baholaydi. Ko'rsatkichning yuqori qiymati aktivlar qadrsizlanishi xavfining ortganidan dalolat beradi. No-tsiklik saraton immunoterapiyasi sektorida haddan tashqari yuqori kredit yuklamasi kompaniyaning ilmiy maqsadlariga erishishdagi moslashuvchanligini cheklashi mumkin. Qarzning past darajasi biznesning makroiqtisodiy tebranishlardan mustaqilligini tasdiqlaydi.
Muhim raqobatchilar
Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati Ascentage Pharma Group AAPG|CGON: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|UroGen Pharma - Uzoq muddatli qarzning kapitalga nisbati|Bicara Therapeutics Inc (BCAX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|PSNL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Erasca Oncology (ERAS)|Uzoq muddatli qarzning o'z kapitaliga nisbati Delcath Systems, Inc.|YMAB: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati AURA (Aura Biosciences)|CADL (candeltx.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati ARAY (Accuray Inc.)|SLS - Uzoq muddatli qarzning o'z kapitaliga nisbati|ACTU: Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR - Uzoq muddatli qarzning kapitalga nisbati|tuhurabio.com (HURA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Protara Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|FATE (Fate Therapeutics Corp) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Aadi Bio WHWK|Uzoq muddatli qarzning o'z kapitaliga nisbati TScan Therapeutics (TCRX)|Uzoq muddatli qarzning o'z kapitaliga nisbati championsoncology.com CSBR|XBiotech - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga nisbati CEL-SCI Corp. CVM|OSTX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti RADX (Radiopharm Theranostics Ltd)|ARTV: Uzoq muddatli qarzning kapitalga nisbati|Adlai Nortye (ANL) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Veru|Uzoq muddatli qarzning o'z kapitaliga nisbati TPST|Uzoq muddatli qarzning o'z kapitaliga nisbati XLO (Xilio Therapeutics, Inc.)|RENB (renovarobio.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati Kairos Pharma KAPA|OnKure Therapeutics, Inc. (OKUR) - Uzoq muddatli majburiyatlarning kapitalga nisbati|GDTC - Uzoq muddatli qarzning o'z kapitaliga nisbati|CRIS (Curis, Inc.) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|APLM: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Tharimmune Corporation|Uzoq muddatli qarzning o'z kapitaliga nisbati Advanced Biomed Inc.|Uzoq muddatli majburiyatlarning kapitalga nisbati genprex.com GNPX|Uzoq muddatli qarzning o'z kapitaliga nisbati Calidi Biotherapeutics (CLDI)|Uzoq muddatli qarzning o'z kapitaliga nisbati SBFM (Sunshine Biopharma Inc.)|Uzoq muddatli qarzning o'z kapitaliga nisbati Xenetic Biosciences, Inc. XBIO|Salarius Pharma (SLRX) - Uzoq muddatli majburiyatlarning kapitalga nisbati|Purple Biotech - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati American Oncology Network (AONC)|BGNE (BeiGene) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Checkpoint Therapeutics Inc. (CKPT)|Uzoq muddatli qarzning o'z kapitaliga nisbati ELEV|ICAD: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati Ikena Oncology, Inc. (IKNA)|NTBL: Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Viracta Therapeutics, Inc. VIRX|MorphoSys Inc - Uzoq muddatli qarzning o'z kapitaliga nisbati|NAYA Bio - Uzoq muddatli qarzning kapitalga nisbati|Ascentage (AAPGV) - Uzoq muddatli qarzning o'z kapitaliga nisbati